Impel NeuroPharma Overview

  • Founded
  • 2008
Founded
  • Status
  • Public
  • Employees
  • 64
Employees
  • Stock Symbol
  • IMPL
Stock Symbol
  • Share Price
  • $5.95
  • (As of Monday Closing)

Impel NeuroPharma General Information

Description

Impel NeuroPharma Inc is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. Its pipeline of proprietary product candidates includes INP107 for the treatment of OFF episodes in Parkinson's Disease.

Contact Information

Website
www.impelnp.com
Ownership Status
Publicly Held
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Drug Delivery
Therapeutic Devices
Stock Exchange
NAS
Primary Office
  • 201 Elliott Avenue West
  • Suite 260
  • Seattle, WA 98119
  • United States
+1 (206) 000-0000

Impel NeuroPharma Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Impel NeuroPharma Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.95 $6.08 $5.92 - $34.75 $140M 23M 133K -$5.44

Impel NeuroPharma Financials Summary

In Thousands,
USD 		TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 185,536
Revenue 91 0 0
EBITDA (64,780) (44,665) (41,524)
Net Income (65,818) (45,798) (41,859)
Total Assets 121,481 12,059 42,265
Total Debt 29,285 8,411 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Impel NeuroPharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Impel NeuroPharma‘s full profile, request access.

Request a free trial

Impel NeuroPharma Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore Impel NeuroPharma‘s full profile, request access.

Request a free trial

Impel NeuroPharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Impel NeuroPharma Inc is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop
Pharmaceuticals
Seattle, WA
64 As of 2021
00000
00000000 00000

0000000

derit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupida
0000 000000000
Cambridge, MA
000 As of 0000
00000
00000000 00000

000000 0

nim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequ
0000 000000000
Aliso Viejo, CA
000 As of 0000
0000
0.00 0000-00-00
000000&0 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Impel NeuroPharma Competitors (27)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sarepta Therapeutics Formerly VC-backed Cambridge, MA 000 00000 00000000 00000
000000 00000000000 Corporate Backed or Acquired Aliso Viejo, CA 000 0000 000000&0 0000
000000 00000000000 Formerly VC-backed Redwood City, CA 00 00000 000000 - 000 00000
00000000 Venture Capital-Backed San Diego, CA 000 00000 000000000 00000
000000000 00000000 Venture Capital-Backed Milwaukee, WI 0 000.00 0000000000 0 000.00
You’re viewing 5 of 27 competitors. Get the full list »

Impel NeuroPharma Patents

  • 94

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 5

    Granted

  • 7

    Pending

  • 000

    Expiring in next 12 mo

Impel NeuroPharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210236485-A1 Repeated administration of dihydroergotamine for treatment of frequent migraine headaches Pending 14-Jan-2020 00000000000
US-20200360627-A1 Single-use nasal delivery device Pending 17-May-2019 0000000000
EP-3906017-A1 Nasal drug delivery device Pending 03-Jan-2019 0000000000
CA-3125430-A1 Nasal drug delivery device Pending 03-Jan-2019 000000000
AU-2019418744-A1 Nasal drug delivery device Pending 03-Jan-2019 A61M15/08
To view Impel NeuroPharma’s complete patent history, request access »

Impel NeuroPharma Executive Team (20)

Name Title Board Seat Contact Info
Adrian Adams Chief Executive Officer & Chairman
John Leaman MD Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
John Hoekman Ph.D Chief Scientific Officer & Founder
Leonard Paolillo Executive and Chief Commercial Officer
Lynn Gold Ph.D Senior Vice President
You’re viewing 5 of 20 executive team members. Get the full list »

Impel NeuroPharma Board Members (13)

Name Representing Role Since
Aaron Royston MD venBio Board Member 000 0000
Adrian Adams Impel NeuroPharma Chief Executive Officer & Chairman 000 0000
Ali Satvat Kohlberg Kravis Roberts Board Member 000 0000
David Allison Ph.D 5AM Ventures Board Member 000 0000
Diane Wilfong Self Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Impel NeuroPharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Impel NeuroPharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Impel NeuroPharma‘s full profile, request access.

Request a free trial